Antares Pharma, Inc. (ATRS) Holdings Boosted by Wells Fargo & Company MN
Wells Fargo & Company MN raised its stake in shares of Antares Pharma, Inc. (NASDAQ:ATRS) by 28.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,335,906 shares of the specialty pharmaceutical company’s stock after acquiring an additional 294,810 shares during the quarter. Wells Fargo & Company MN’s holdings in Antares Pharma were worth $4,328,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital Advantage Inc. purchased a new position in Antares Pharma during the third quarter valued at $110,000. Alliancebernstein L.P. purchased a new position in shares of Antares Pharma in the second quarter worth about $119,000. Legal & General Group Plc purchased a new position in shares of Antares Pharma in the second quarter worth about $120,000. MML Investors Services LLC lifted its stake in shares of Antares Pharma by 228.2% in the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 30,000 shares in the last quarter. Finally, First Eagle Investment Management LLC lifted its stake in shares of Antares Pharma by 150.0% in the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock worth $162,000 after buying an additional 30,000 shares in the last quarter. 34.63% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.60% of the stock is currently owned by company insiders.
Several equities analysts have recently weighed in on the stock. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research note on Friday, October 13th. Piper Jaffray Companies set a $3.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research note on Monday, October 23rd. BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Finally, ValuEngine downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Antares Pharma has a consensus rating of “Buy” and an average price target of $3.84.
Antares Pharma, Inc. (ATRS) opened at $2.22 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34. Antares Pharma, Inc. has a 52 week low of $1.58 and a 52 week high of $4.09.
Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The firm had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.01 million. Antares Pharma’s quarterly revenue was up 11.9% on a year-over-year basis. equities analysts expect that Antares Pharma, Inc. will post -0.11 EPS for the current year.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma, Inc. (NASDAQ:ATRS).
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.